BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (Nasdaq - KRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (Nasdaq - XAGE), Southern States Bancshares, Inc. (Nasdaq

BALA CYNWYD, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Regulus Therapeutics Inc. (Nasdaq – RGLS)

Under the terms of the Merger Agreement, Regulus will be acquired by Novartis AG (“Novartis”) for an initial payment of $7.00 per share in cash at closing, or $0.8 billion. In addition, Regulus shareholders will receive a contingent value right providing for payment of $7.00 per share, contingent upon the achievement of a milestone with respect to regulatory approval of Regulus’ lead product candidate, farabursen. The investigation concerns whether the Regulus Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the Company’s shareholders are receiving fair value for their shares.

Additional information can be found at https://www.brodskysmith.com/cases/regulus-therapeutics-inc-nasdaq-rgls/.

Kronos Bio, Inc. (Nasdaq - KRON)

Under the terms of the agreement, Kronos will be acquired by Concentra Biosciences, LLC (“Concentra”) for $0.57 in cash per share of Kronos Bio common stock, plus one non-tradeable contingent value right (“CVR”). The investigation concerns whether the Kronos Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the Company’s shareholders are receiving fair value for their shares.

Additional information can be found at https://www.brodskysmith.com/cases/kronos-bio-inc-nasdaq-kron/.

Longevity Health Holdings, Inc. (Nasdaq - XAGE)

Under the terms of the Merger Agreement, Longevity Health will merge with 20/20 BioLabs, Inc. (“20/20”). Upon the close of the transaction, Longevity Health shareholders will own approximately 49.9% of the combined company. The investigation concerns whether the Longevity Health Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of Company shareholders in the combined company.

Additional information can be found at https://www.brodskysmith.com/cases/longevity-health-holdings-inc-nasdaq-xage/.

Southern States Bancshares, Inc. (Nasdaq - SSBK)

Under the terms of the Merger Agreement, Southern States will be acquired by FB Financial Corporation. Southern States shareholders will receive 0.800 shares of FB Financial common stock for each share of Southern States stock. Based on FB Financial’s closing stock price of $47.05 per share as of March 28, 2025, the implied transaction value is approximately $37.64 per Southern States share, or $381 million, in the aggregate. The investigation concerns whether the Southern States Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the Company’s shareholders are receiving fair value for their shares.

Additional information can be found at https://www.brodskysmith.com/cases/southern-states-bancshares-inc-nasdaq-ssbk/.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.